NCT06196801View on ClinicalTrials.gov

Efficacy of Triple-Combination Therapy in Severe PAH-CHD

Active, not recruitingOBSERVATIONAL
Enrollment

80

Participants

Timeline

Start Date

June 17, 2022

Primary Completion Date

December 1, 2025

Study Completion Date

December 1, 2025

Conditions
Congenital Heart DiseasePulmonary Arterial Hypertension
Interventions
DRUG

Triple-combination therapy

phosphodiesterase 5 inhibitors, endothelin receptor antagonist, and parenteral prostacyclin

Trial Locations (1)

510080

Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou

All Listed Sponsors
lead

Guangdong Provincial People's Hospital

OTHER